150 filings
6-K
CVAC
CureVac N.V.
17 Jan 24
CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock
9:02am
6-K
CVAC
CureVac N.V.
5 Jan 24
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development
4:15pm
6-K
CVAC
CureVac N.V.
19 Dec 23
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
4:30pm
6-K
CVAC
CureVac N.V.
14 Nov 23
Current report (foreign)
4:15pm
6-K
CVAC
CureVac N.V.
14 Nov 23
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
4:15pm
6-K
27o4ercw
1 Nov 23
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
4:45pm
UPLOAD
2hqs6k1tp 65p1oiz
19 Oct 23
Letter from SEC
12:00am
20-F/A
5f767h 4k
12 Oct 23
Annual report (foreign) (amended)
4:15pm
CORRESP
vt8iom q9drcluza
10 Oct 23
Correspondence with SEC
12:00am
6-K
uj7yuzmsi1lnolsyh gt
28 Sep 23
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
4:30pm
UPLOAD
s4it ebmesdm
26 Sep 23
Letter from SEC
12:00am
6-K
q55ggdw3ct f07xv10
12 Sep 23
Current report (foreign)
4:30pm
6-K
ug7mzvmht0b be
17 Aug 23
Current report (foreign)
4:30pm
6-K
t4pa uj33
17 Aug 23
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
4:30pm
6-K
2hg vu5ae7
1 Aug 23
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
4:15pm
6-K
anek6sv qx5scvk
14 Jul 23
CureVac Announces Update to the Management Team
4:01pm
6-K
9al0fd
13 Jul 23
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
4:01pm
6-K
bgdlb
22 Jun 23
Current report (foreign)
4:01pm
6-K
6vbnwayzos 42kod
20 Jun 23
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
4:45pm
6-K
jdc0r4weh
20 Jun 23
Current report (foreign)
4:45pm